Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05651100

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Phase 1/Phase 2 Study of Sequential Chimeric Antigen Receptor T Cell Targeting at CD19 and CD22 B-cell Antigens Treating Refractory or Relapsed B-cell Lymphoma Patients

Sponsor: Hebei Yanda Ludaopei Hospital

Conditions Lymphoma, B-Cell

Interventions CD19 and CD22 targeted CAR-T cells

Updated 4 times since 2023 Last updated: Dec 6, 2022 Started: Dec 10, 2022 Primary completion: Dec 10, 2024 Completion: Dec 10, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Lymphoma, B-Cell and is currently ongoing. Hebei Yanda Ludaopei Hospital leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE1/PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Not Yet Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Dec 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hebei Yanda Ludaopei Hospital
Kecellitics Biotech Company Ltd

Data source: Kecellitics Biotech Company Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Langfang, China